DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT01834248 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Alkylating Agent-Related Acute Myeloid Leukemia
Chronic Myelomonocytic Leukemia
Myelodysplastic Syndrome
Refractory Anemia With Excess Blasts in Transformation

Interventions

BIOLOGICAL: DEC-205/NY-ESO-1 Fusion Protein CDX-1401
DRUG: Decitabine
OTHER: Laboratory Biomarker Analysis
DRUG: Poly ICLC

Sponsor

Roswell Park Cancer Institute